More than three years after Merck KGaA decided to dump its partnership with Milan-based Newron Pharmaceuticals, which in turn iced a planned buyout by Biotie, the Italian biotech has persevered to win European approval to market safinamide as an add-on drug for Parkinson’s disease.

…read more

Source: After painful odyssey, Newron wins European OK for Parkinson’s add-on